GRI Bio (GRI) Competitors $1.47 +0.03 (+2.08%) As of 07/7/2025 03:57 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GRI vs. LPTX, BTAI, XFOR, PHXM, CSCI, AIMD, BCLI, PHIO, ACXP, and NLSPShould you be buying GRI Bio stock or one of its competitors? The main competitors of GRI Bio include Leap Therapeutics (LPTX), BioXcel Therapeutics (BTAI), X4 Pharmaceuticals (XFOR), PHAXIAM Therapeutics (PHXM), COSCIENS Biopharma (CSCI), Ainos (AIMD), Brainstorm Cell Therapeutics (BCLI), Phio Pharmaceuticals (PHIO), Acurx Pharmaceuticals (ACXP), and NLS Pharmaceutics (NLSP). These companies are all part of the "pharmaceutical products" industry. GRI Bio vs. Its Competitors Leap Therapeutics BioXcel Therapeutics X4 Pharmaceuticals PHAXIAM Therapeutics COSCIENS Biopharma Ainos Brainstorm Cell Therapeutics Phio Pharmaceuticals Acurx Pharmaceuticals NLS Pharmaceutics Leap Therapeutics (NASDAQ:LPTX) and GRI Bio (NASDAQ:GRI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk. Is LPTX or GRI more profitable? Leap Therapeutics' return on equity of -162.15% beat GRI Bio's return on equity.Company Net Margins Return on Equity Return on Assets Leap TherapeuticsN/A -162.15% -120.05% GRI Bio N/A -275.15%-168.22% Does the media prefer LPTX or GRI? In the previous week, GRI Bio had 1 more articles in the media than Leap Therapeutics. MarketBeat recorded 2 mentions for GRI Bio and 1 mentions for Leap Therapeutics. GRI Bio's average media sentiment score of 0.57 beat Leap Therapeutics' score of 0.00 indicating that GRI Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Leap Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GRI Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings and valuation, LPTX or GRI? Leap Therapeutics is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLeap TherapeuticsN/AN/A-$67.56M-$1.70-0.17GRI BioN/AN/A-$8.21M-$11.56-0.13 Do analysts rate LPTX or GRI? Leap Therapeutics currently has a consensus price target of $3.38, suggesting a potential upside of 1,089.22%. GRI Bio has a consensus price target of $22.00, suggesting a potential upside of 1,396.60%. Given GRI Bio's stronger consensus rating and higher possible upside, analysts clearly believe GRI Bio is more favorable than Leap Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Leap Therapeutics 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00GRI Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, LPTX or GRI? Leap Therapeutics has a beta of -0.28, suggesting that its share price is 128% less volatile than the S&P 500. Comparatively, GRI Bio has a beta of -1.62, suggesting that its share price is 262% less volatile than the S&P 500. Do institutionals and insiders have more ownership in LPTX or GRI? 30.5% of Leap Therapeutics shares are owned by institutional investors. Comparatively, 34.0% of GRI Bio shares are owned by institutional investors. 7.5% of Leap Therapeutics shares are owned by insiders. Comparatively, 0.1% of GRI Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryGRI Bio beats Leap Therapeutics on 8 of the 13 factors compared between the two stocks. Get GRI Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for GRI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRI vs. The Competition Export to ExcelMetricGRI BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.08M$2.91B$5.52B$9.02BDividend YieldN/A2.44%5.24%4.08%P/E Ratio-0.1320.3027.1920.04Price / SalesN/A250.25413.81108.84Price / CashN/A41.7026.2128.59Price / Book0.197.397.925.55Net Income-$8.21M-$55.04M$3.17B$248.49M7 Day Performance7.30%2.51%1.78%4.87%1 Month Performance6.52%-0.21%1.26%6.63%1 Year Performance-94.73%3.41%33.30%20.38% GRI Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRIGRI Bio3.269 of 5 stars$1.47+2.1%$22.00+1,396.6%-94.5%$3.08MN/A-0.131LPTXLeap Therapeutics1.3865 of 5 stars$0.30+13.5%$3.38+1,036.7%-85.8%$10.84MN/A-0.1740Gap DownBTAIBioXcel Therapeutics4.5179 of 5 stars$1.81+2.3%$42.60+2,253.6%-88.7%$10.72M$2.27M-0.1390Positive NewsGap UpXFORX4 Pharmaceuticals4.6529 of 5 stars$1.90+3.8%$72.33+3,707.0%-89.8%$10.59M$2.56M0.8980High Trading VolumePHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049CSCICOSCIENS BiopharmaN/A$3.40+1.8%N/AN/A$10.51M$9.59M-0.5920Gap DownAIMDAinos0.5985 of 5 stars$2.83+13.2%N/A-19.9%$10.48M$20K-2.1940BCLIBrainstorm Cell Therapeutics4.0772 of 5 stars$1.12+5.7%$30.00+2,578.6%-79.2%$10.43MN/A-0.3340PHIOPhio Pharmaceuticals2.1725 of 5 stars$2.35+8.3%$14.00+495.7%-51.4%$10.41MN/A-0.3710News CoverageACXPAcurx Pharmaceuticals2.5839 of 5 stars$0.51+18.8%$8.00+1,466.2%-77.1%$10.10MN/A-0.733Gap UpNLSPNLS PharmaceuticsN/A$2.90+3.9%N/A+1,101.1%$10.04MN/A0.006Analyst Upgrade Related Companies and Tools Related Companies LPTX Alternatives BTAI Alternatives XFOR Alternatives PHXM Alternatives CSCI Alternatives AIMD Alternatives BCLI Alternatives PHIO Alternatives ACXP Alternatives NLSP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRI) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredInstant Cash (in 4 clicks)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GRI Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GRI Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GRI Stock Alerts